Cannabidiol ameliorates cognitive and motor impairment in mice with bile duct ligation, a model of hepatic encephalopathy. Cannabidiol administration may thus represent an adjunct treatment dealing with the central nervous system symptoms secondary to liver disease, along with other drugs improving liver function. Cannabidiol is also an inhibitor of ID-1 gene expression in aggressive breast cancer cells. Cannabigerol inhibits keratinocyte proliferation in a concentration-dependent manner. It is a partial agonist at both the CB1 and CB2 cannabinoid receptors. The CB2 receptor is involved in the pathogenesis of experimental encephalopathy in mice, caused by thioacetamide-induced acute liver failure. This is an animal model for hepatic encephalopathy, a neuropsychiatric syndrome. Cannabinoid and endocannabinoid chemistry, biochemistry and pharmacology continue to be active fields of research. While advances in these areas have widened our understanding of numerous physiological processes and pathological states, there are as yet no new major cannabinoid therapeutic agents.